Biblio
Found 11 results
Filters: Author is Wiedmer, L. [Clear All Filters]
Atomistic and thermodynamic analysis of N6-methyladenosine (mA) recognition by the reader domain of YTHDC1. Journal of Chemical Theory and Computation. 17(2):1240-1249.
.
2021. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. Journal of General Virology. 102(7)
.
2021. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem. 16(19):3035-3043.
.
2021. Hitting a moving target: simulation and crystallography study of ATAD2 bromodomain blockers. ACS Medicinal Chemistry Letters. 11(8):1573-1580.
.
2020. Selectively disrupting m6A-dependent protein-RNA interactions with fragments. ACS Chemical Biology. 15(3):618-625.
.
2020. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem. 15(9):744-748.
.
2020. Flexible binding of m6A reader protein YTHDC1 to its preferred RNA motif. Journal of Chemical Theory and Computation. 15(12):7004-7014.
.
2019. Ligand retargeting by binding site analogy. European Journal of Medicinal Chemistry. 175:107-113.
.
2019. A reader-based assay for m6A writers and erasers. Analytical Chemistry. 91(4):3078-3084.
.
2019. In silico identification of JMJD3 demethylase inhibitors. Journal of Chemical Information and Modeling. 58(10):2151–2163.
.
2018. Fragment-based design of selective nanomolar ligands of the CREBBP bromodomain. Journal of Medicinal Chemistry. 59(4):1350-1356.
.
2016.